MagnetisMM-30
A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1
- Enrollment
- 100 patients (estimated)
- Sponsors
- Pfizer
- Collaborators
- Bristol Myers Squibb
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1830
- NCT Identifier
- NCT06215118
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.